0001209191-21-068388.txt : 20211207 0001209191-21-068388.hdr.sgml : 20211207 20211207174406 ACCESSION NUMBER: 0001209191-21-068388 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211130 FILED AS OF DATE: 20211207 DATE AS OF CHANGE: 20211207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WALDRON RICHARD A CENTRAL INDEX KEY: 0001226961 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39787 FILM NUMBER: 211477018 MAIL ADDRESS: STREET 1: 901 MARINERS ISLAND BLVD STE.205 CITY: SAN MATEO STATE: CA ZIP: 94404 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BioAtla, Inc. CENTRAL INDEX KEY: 0001826892 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 851922320 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11085 TORREYANA ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-558-0708 MAIL ADDRESS: STREET 1: 11085 TORREYANA ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-11-30 0 0001826892 BioAtla, Inc. BCAB 0001226961 WALDRON RICHARD A C/O BIOATLA, INC. 11085 TORREYANA ROAD SAN DIEGO CA 92121 0 1 0 0 Chief Financial Officer Common Stock 2021-11-30 2021-12-03 4 S 0 2240 23.997 D 146419 D Common Stock 2021-11-30 2021-12-03 4 S 0 2422 24.676 D 143997 D Common Stock 2021-11-30 2021-12-03 4 S 0 848 25.379 D 143149 D Common Stock 2021-12-01 2021-12-06 4 S 0 2332 22.186 D 140817 D Common Stock 2021-12-01 2021-12-06 4 S 0 4034 23.266 D 136783 D Common Stock 2021-12-01 2021-12-06 4 S 0 880 24.224 D 135903 D Common Stock 2021-12-02 2021-12-06 4 S 0 1405 21.741 D 134498 D Common Stock 2021-12-02 2021-12-06 4 S 0 29 22.471 D 134469 D Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs. The range of prices for the shares of Common Stock is from $23.33 to $24.32. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. The range of prices for the shares of Common Stock is from $24.33 to $25.25. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. The range of prices for the shares of Common Stock is from $25.30 to $25.38. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. The range of prices for the shares of Common Stock is from $21.79 to $22.73. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. The range of prices for the shares of Common Stock is from $22.79 to $23.77. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. The range of prices for the shares of Common Stock is from $23.80 to $24.68. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. The range of prices for the shares of Common Stock is from $21.40 to $22.37. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. The range of prices for the shares of Common Stock is from $22.40 to $22.51. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. /s/ Christian Vasquez, as Attorney-in-Fact for Richard A. Waldron 2021-12-07